Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from NKGen Biotech ( (NKGN) ).
On January 20, 2026, NKGen Biotech, Inc. and Meteora-affiliated entities amended their existing forward purchase agreement for OTC equity prepaid forward transactions, extending the agreement’s valuation date to December 31, 2026 while leaving all other terms unchanged. On January 23, 2026, NKGen Biotech and its operating subsidiary entered into a second amendment to a secured promissory note with AlpineBrook Capital GP I Limited, providing an additional $372,000 in funding, increasing the note’s principal to $26,507,106 and specifying that interest on the new loan portion accrues from January 23, 2026, steps that bolster the company’s liquidity and clarify its financing costs for stakeholders.
More about NKGen Biotech
NKGen Biotech, Inc., formerly known as Graf Acquisition Corp. IV, operates in the biotechnology sector and is focused on advancing its operations and financing structure through capital markets transactions and secured lending arrangements, including forward purchase agreements and promissory notes with institutional investors.
Average Trading Volume: 7,204
Technical Sentiment Signal: Sell
Current Market Cap: $7.46M
See more insights into NKGN stock on TipRanks’ Stock Analysis page.